Selecta Biosciences Receives $9.35M

selectaSelecta Biosciences, a Watertown, Mass.-based clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, received a total of $9.35m in new funding.

The Bill and Melinda Gates Foundation provided a $1.25m grant for malaria vaccines while the National Institutes of Health (NIH) awarded an $8.1m grant for nicotine vaccine for smoking cessation and relapse prevention.

Led by Werner Cautreels, Ph.D., President and CEO, Selecta Biosciences develops novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. The company, which has just announced a new product candidate for its pipeline of tolerogenic immunotherapies, SEL-212, a non-immunogenic treatment for refractory and tophaceous gout, is now developing products for three applications of antigen-specific tolerance, the inhibition of immunogenicity for biologic therapies, treatment of allergies, and treatment of autoimmune diseases.



Join the discussion